Head to Head Comparison: Tenaya Therapeutics (NASDAQ:TNYA) & Corvus Pharmaceuticals (NASDAQ:CRVS)

Tenaya Therapeutics (NASDAQ:TNYA) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 48.7% of Tenaya Therapeutics shares are held by insiders. Comparatively, 28.5% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Tenaya Therapeutics and Corvus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1	0	4	0	2.60
Corvus Pharmaceuticals	1	0	5	0	2.67

Tenaya Therapeutics presently has a consensus target price of $4.50, suggesting a potential upside of 516.86%. Corvus Pharmaceuticals has a consensus target price of $14.25, suggesting a potential upside of 77.02%. Given Tenaya Therapeutics’ higher probable upside, equities analysts clearly believe Tenaya Therapeutics is more favorable than Corvus Pharmaceuticals.

Profitability

This table compares Tenaya Therapeutics and Corvus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-95.46%	-76.79%
Corvus Pharmaceuticals	N/A	-26.11%	-20.48%

Valuation and Earnings

This table compares Tenaya Therapeutics and Corvus Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$111.13 million	($0.78)	-0.94
Corvus Pharmaceuticals	N/A	N/A	-$62.29 million	($0.53)	-15.19

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Tenaya Therapeutics has a beta of 3.18, meaning that its stock price is 218% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Summary

Corvus Pharmaceuticals beats Tenaya Therapeutics on 6 of the 11 factors compared between the two stocks.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.